Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Colorectal cancer (CRC) is the third most common cancer in the world with 150,000 new cases each year. At initial diagnosis, 20% of patients have distant metastasis, thus the cancer has spread to other parts and organs of the body and is not confined to the colon or rectum. 25% to 30% of patients with early stage disease will develop metastasis consequently. The subsequent duration of life for metastatic untreated patients is a heart-aching number accounting for a maximum of 9 months.

Currently, using combination therapy approaches, overall survival lengths has been extended to 20 months. The standard of care for metastatic CRC is surgery followed by chemotherapy. There are several approved chemotherapeutic drugs, one of which is the administration of 5-fluorouracil (5FU) with oxaliplatin given mainly through the course of 12 month,s biweekly. The response rate for this treatment is 29%.

Therapy based upon the biology of an individual’s tumour rather than established histopathologic and anatomic classification is an approach that promises to optimise the use of existing therapies. Gene expression analysis offers the potential to measure genome-wide activity which can be used to predict response to current treatments. My project aims at creating a predictive model that can determine which patients are sensitive or resistant to different chemotherapeutic treatment.

In the future, if we, or any other research group, succeeded in reaching this purpose, we would be able to identify the 71% of patients who may not benefit from chemotherapy. I think modifying the standard of care for CRC will have impactful results on the life of patients and this is our ultimate goal as cancer researchers.

Blog posts

I can’t see you; I can’t hear you; how do I engage you?

Working from home is a lonely business, so the chance to meet and engage people with our science was too good to pass up. Schools and work places are not the only places that have to operate remotely. Across the UK clubs, societies and groups are using the internet to keep their interests alive.

Prostate Cancer – March 2020

For prostate cancer awareness month, we focus on the work of Dr Valentine Macaulay.

Brain tumours; like finding a needle in a haystack?!

For Brain Tumour Awareness Month, Vanessa Johanssen talks about her work and how their research has helped to find brain tumours when they're small enough to treat.

Discovering Common Ground

Last April we joined forces with Corpus Christi College and visited Crewe to talk to students there about the impact of maths in materials and cancer research. We met Sarah Stubington and discovered that a shared love of science can create common ground. Sarah shared her perspective of our meeting.

Physics in Medicine

When I was in secondary school, I had two great loves: physics and medicine, in that order. It seemed to me at the time, that these were polar opposites. When I chose to study physics, that meant leaving medicine behind, of course, they’re different fields! That was 6 years ago, so it would surprise my younger self to learn that in 2020, I work in a hospital.